Gut-Immune-Brain Axis Clinical Trial for Parkinson's Disease
Trial Overview
flowchart TD
Gut_Immune_Brain_Axis_Clinical["Gut-Immune-Brain Axis Clinical Trial for Parkins"]
Gut_Immune_Brain_Axis_Clinical["Gut-Immune-Brain"]
Gut_Immune_Brain_Axis_Clinical -->|"related to"| Gut_Immune_Brain_Axis_Clinical
style Gut_Immune_Brain_Axis_Clinical fill:#81c784,stroke:#333,color:#000
Gut_Immune_Brain_Axis_Clinical["Axis"]
Gut_Immune_Brain_Axis_Clinical -->|"related to"| Gut_Immune_Brain_Axis_Clinical
style Gut_Immune_Brain_Axis_Clinical fill:#81c784,stroke:#333,color:#000
Gut_Immune_Brain_Axis_Clinical["Parkinson"]
Gut_Immune_Brain_Axis_Clinical -->|"related to"| Gut_Immune_Brain_Axis_Clinical
style Gut_Immune_Brain_Axis_Clinical fill:#81c784,stroke:#333,color:#000
style Gut_Immune_Brain_Axis_Clinical fill:#4fc3f7,stroke:#333,color:#000
This clinical trial tests gut-immune axis modulation in [Parkinson's disease](/diseases/parkinsons-disease) patients using a combination of prebiotic/probiotic/Vitamin D therapy. The study is based on growing evidence that the [gut-brain axis](/mechanisms/neuroinflammation) plays a critical role in [neurodegeneration](/diseases/parkinsons-disease) and that [alpha-synuclein](/proteins/alpha-synuclein) pathology may originate in the enteric nervous system before spreading to the brain["@braak2003"][@braak2003a].
Rationale and Background
The Gut-Brain Axis in Parkinson's Disease
...Gut-Immune-Brain Axis Clinical Trial for Parkinson's Disease
Trial Overview
Mermaid diagram (expand to render)
This clinical trial tests gut-immune axis modulation in [Parkinson's disease](/diseases/parkinsons-disease) patients using a combination of prebiotic/probiotic/Vitamin D therapy. The study is based on growing evidence that the [gut-brain axis](/mechanisms/neuroinflammation) plays a critical role in [neurodegeneration](/diseases/parkinsons-disease) and that [alpha-synuclein](/proteins/alpha-synuclein) pathology may originate in the enteric nervous system before spreading to the brain["@braak2003"][@braak2003a].
Rationale and Background
The Gut-Brain Axis in Parkinson's Disease
The [gut-brain axis](/mechanisms/neuroinflammation) in Parkinson's disease involves complex bidirectional communication between the intestinal microbiome, the immune system, and the central nervous system. This connection has become increasingly recognized as a key factor in PD pathogenesis[@sampson2016][@poewe2022].
Evidence for Gut Origin of PD
Several lines of evidence support the hypothesis that Parkinson's disease may originate in the gut:
- Gastrointestinal Symptoms: [Parkinson's disease](/diseases/parkinsons-disease) patients often exhibit gastrointestinal symptoms, particularly constipation, years before motor symptoms appear[@savica2010][@postuma2015]
- Alpha-Synuclein Pathology: [Alpha-synuclein](/proteins/alpha-synuclein) aggregates (the key pathological protein in PD) have been found in the enteric nervous system of PD patients, and these aggregates may travel via the vagus nerve to the brain[@braak2003b][@shannon2013]
- Genetic Factors: [LRRK2](/genes/lrrk2) mutations (one of the most common genetic causes of PD) are expressed in immune cells and may affect immune function[@gardet2010][@wandinger2011]
- Microbiome Alterations: Altered gut microbiome composition has been consistently reported in PD patients compared to healthy controls[@keshavarzian2015][@hillburns2017]
The Microbiome-Gut-Brain Communication
The gut microbiome communicates with the brain through multiple pathways:
Vagal Afferents: The vagus nerve provides direct neural connection between gut and brain
Metabolites: Short-chain fatty acids (SCFAs) produced by gut bacteria cross the blood-brain barrier
Immune System: Gut-associated lymphoid tissue (GALT) primes systemic immune responses
Endocrine Pathways: Gut hormones and neurotransmitters enter systemic circulationRole of Inflammation in PD
Chronic [neuroinflammation](/mechanisms/neuroinflammation) is a hallmark of Parkinson's disease, characterized by activated microglia and elevated pro-inflammatory cytokines[@hirsch2012][@tansey2022]:
- IL-1β: Elevated in PD brains and CSF
- IL-6: Associated with disease progression
- TNF-α: Found in substantial amounts in substantia nigra of PD patients
- CRP: Systemic inflammation marker elevated in PD
The gut microbiome influences systemic inflammation through microbial metabolite production and immune cell modulation[@erny2015][@burokas2017].
Vitamin D and Neuroprotection
Vitamin D has multiple potential neuroprotective effects:
- Modulation of microglia activation
- Protection against oxidative stress
- Regulation of calcium homeostasis
- Support for neurotrophic factor production
- Immunomodulatory properties
Vitamin D deficiency has been associated with increased PD risk and severity[@evatt2008][@fullard2010].
Study Design
Phase and Duration
Phase: Phase 2, randomized, double-blind, placebo-controlled
Duration: 30 months (including 6-month follow-up after treatment period)
Enrollment
Target Enrollment: 120 [Parkinson's disease](/diseases/parkinsons-disease) patients
Power Calculation: 80% power to detect 4-point difference in MDS-UPDRS Part III at α=0.05
Arms
Active Treatment: Prebiotic fiber + Probiotic + Vitamin D3
Placebo Control: Matching placeboRandomization
Stratified randomization by:
- Disease duration (< 5 years vs ≥ 5 years)
- Hoehn & Yahr stage (1-2 vs 3)
- Vitamin D status (deficient vs sufficient)
Inclusion Criteria
- Age 40-80 years
- Diagnosis of [Parkinson's disease](/diseases/parkinsons-disease) according to UK Brain Bank criteria
- Hoehn & Yahr stage 1-3
- Stable PD medications for at least 4 weeks prior to enrollment
- No significant cognitive impairment (MoCA ≥ 24)
- Able to provide informed consent
- Willingness to comply with study procedures
Exclusion Criteria
- Recent antibiotics (within 4 weeks)
- Probiotic or prebiotic supplementation (within 4 weeks)
- Gastrointestinal disorders (IBD, celiac disease, IBS requiring medication)
- Immunocompromised state
- Serum 25-hydroxyvitamin D > 100 ng/mL (to avoid vitamin D toxicity)
- History of hypercalcemia
- Current participation in other clinical trials
- Significant medical conditions that may interfere with participation
- Pregnancy or breastfeeding
Endpoints
Primary Endpoints
Motor Symptoms: Change in MDS-UPDRS Part III (motor score) from baseline to 24 months
Inflammatory Biomarkers: Change in serum IL-6, TNF-α, and CRP from baseline to 24 monthsSecondary Endpoints
Gut Microbiome: Change in gut microbiome composition (alpha and beta diversity, relative abundance of key taxa)
Non-Motor Symptoms: Change in Non-Motor Symptoms Scale (NMSS)
Quality of Life: Change in PDQ-39
Vitamin D Status: Change in serum 25-hydroxyvitamin D levels
Cognitive Function: Change in MoCA score
Motor Fluctuations: Change in ON-OFF time diary
Constipation: Change in bowel movement frequencyExploratory Endpoints
CSF Biomarkers: Subset analysis of α-synuclein, tau, and neurofilament light chain in cerebrospinal fluid
Microbiome Metabolites: Fecal SCFA levels
Immune Cell Phenotyping: Peripheral blood mononuclear cell analysisIntervention Details
Active Arm
| Component | Dose | Timing |
|-----------|------|--------|
| Prebiotic fiber (inulin-type) | 10g/day | Once daily with breakfast |
| Probiotic (Bifidobacterium + Lactobacillus) | 10^10 CFU/day | Once daily |
| Vitamin D3 | 4000 IU/day | Once daily |
Placebo Arm
Matching placebo for each component:
- Maltodextrin for prebiotic
- Heat-killed probiotic for probiotic
- Lookalike capsule for vitamin D
Adherence Monitoring
- Daily diary completion
- Pill counts at each visit
- Serum probiotic quantification (subset)
Mechanism of Action
The intervention targets multiple pathways in the [gut-brain axis](/mechanisms/neuroinflammation):
1. Gut Microbiome Modulation
Prebiotics (inulin-type fructans) and probiotics work synergistically to:
- Promote beneficial bacteria (Bifidobacteria, Lactobacilli)
- Increase short-chain fatty acid (SCFA) production
- Reduce intestinal permeability (leaky gut)
- Decrease endotoxin translocation
SCFAs, particularly butyrate, have anti-inflammatory properties and can cross the blood-brain barrier to modulate microglia[@bologna2021][@silva2020].
2. Immune System Regulation
Certain probiotic strains can modulate [neuroinflammation](/mechanisms/neuroinflammation) by:
- Reducing pro-inflammatory cytokines (IL-6, TNF-α)
- Increasing anti-inflammatory cytokines (IL-10)
- Promoting regulatory T cells
- Modulating microglia activation
3. Vitamin D Immunomodulation
Vitamin D exerts neuroprotective effects through:
- Inhibition of microglia activation
- Reduction of nitric oxide production
- Protection against oxidative stress
- Support for neurotrophic factor production (BDNF)
- Regulation of autophagy
4. Combined Effect Hypothesis
The combination approach targets multiple mechanisms simultaneously, potentially producing synergistic effects.
Statistical Analysis
Sample Size and Power
- Sample size: 60 per arm
- Expected dropout: 15%
- Power: 80% (α=0.05)
- Effect size: 0.5 (medium effect)
Primary Analysis
Mixed-effects model with repeated measures (MMRM):
- Fixed effects: treatment, time, treatment × time
- Random effect: participant
- Covariates: baseline value, disease duration, age
Secondary Analyses
- Per-protocol analysis
- Subgroup analyses by baseline vitamin D status, microbiome composition
- Sensitivity analyses for missing data
Analysis Plan
- Intention-to-treat (ITT) population
- Safety population: all participants who received at least one dose
- Per-protocol population: participants with ≥ 80% adherence
Budget
| Category | Cost (USD) |
|----------|------------|
| Personnel (PI, coordinators, nurses) | $400,000 |
| Study drug (active and placebo) | $150,000 |
| Biomarker assays | $200,000 |
| Microbiome sequencing | $180,000 |
| MRI imaging (subset) | $120,000 |
| Clinical laboratory | $80,000 |
| Administrative costs | $120,000 |
| Contingency (15%) | $187,000 |
| Total | $1,437,000 |
Timeline
| Month | Milestone |
|-------|-----------|
| 0-3 | IRB approval, regulatory submissions, site setup |
| 3-6 | Patient recruitment initiation |
| 6-18 | Active patient recruitment |
| 18-24 | Treatment period for last-enrolled patient |
| 24-27 | Follow-up assessments |
| 27-30 | Data analysis, manuscript preparation |
| 30+ | Publication, regulatory reporting |
Expected Outcomes and Risks
Expected Outcomes
- Reduced systemic inflammation: Decrease in IL-6, TNF-α, CRP
- Improved motor symptoms: Lower MDS-UPDRS Part III scores
- Altered gut microbiome: Increased SCFA-producing bacteria
- Potential disease modification: Slower motor progression
Risks and Mitigations
Gastrointestinal discomfort: Start with lower dose, titrate up
Vitamin D toxicity: Monitor serum levels regularly
Probiotic infection: Use strains with excellent safety profiles
Placebo response: Ensure proper blinding
- [Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation)
- [Alpha-Synuclein Aggregation in PD](/mechanisms/alpha-synuclein-pd)
- [Gut-Brain Axis](/entities/gut-brain-axis)
- [Microbiome and Neurodegeneration](/mechanisms/microbiome-neurodegeneration)
- [Vitamin D Signaling in Neuroprotection](/mechanisms/vitamin-d-neuroprotection)
- [LRRK2 and Immune Function](/genes/lrrk2)
- [Clinical Trials in Parkinson's Disease](/clinical-trials/parkinsons)
- [Promising Clinical Trials in Neurodegenerative Diseases](/clinical-trials/promising)
- [Linked Clinical Trials (Cure Parkinson's Trust)](/clinical-trials/linked)
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Clinical Trials in Parkinson's Disease](/clinical-trials/parkinsons)
References
[Braak et al., Staging of brain pathology related to sporadic Parkinson's disease (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/14532271/)
[Braak et al., Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be initiated (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12621350/)
[Sampson et al., Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27739530/)
[Poewe et al., Parkinson's disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/36000812/)
[Savica et al., Medical records and longitudinal studies: Do they tell the same story about the emergence of Parkinson's disease? (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20306062/)
[Postuma et al., Identifying prodromal Parkinson's disease (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26487579/)
[Braak et al., Staging of brain pathology related to sporadic Parkinson's disease (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/14532271/)
[Shannon et al., Intestinal dysmotility contributes to alpha-synuclein pathology (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/24312225/)
[Gardet et al., LRRK2 is expressed in B cells (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20077548/)
[Wandinger et al., LRRK2 and immune cells (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21344673/)
[Keshavarzian et al., Colonic inflammation in Parkinson's disease (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25561235/)
[Hill-Burns et al., Parkinson's disease and Parkinson's disease medications have distinct signatures in the microbiome (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28028168/)
[Hirsch et al., Neuroinflammation in Parkinson's disease (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22293358/)
[Tansey et al., Neuroinflammatory mechanisms in Parkinson's disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35130841/)
[Erny et al., Host microbiota constantly control maturation and function of microglia (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25594188/)
[Burokas et al., Targeting the microbiota-gut-brain axis (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28220784/)
[Evatt et al., Prevalence of vitamin D insufficiency (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18684022/)
[Fullard et al., Vitamin D and the risk of Parkinson's disease (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20081827/)
[Bologna et al., Short chain fatty acids and neuroinflammation (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34160447/)
[Silva et al., Butyrate and neuroinflammation (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32799459/)